Документ о соглашении экспертов по блокаторам β-адренергических рецепторов
Аннотация
Рабочая группа Европейского общества кардиологов по бета-блокаторам
Члены рабочей группы: José López-Sendón (Председатель, Испания), Karl Swedberg (Швеция), John McMurray (Великобритания), Juan Tamargo (Испания), Aldo P. Maggioni (Италия), Henry Dargie (Великобритания), Michal Tendera (Польша), Finn Waagstein (Швеция), Jan Kjekshus (Норвегия), Philippe Lechat (Франция), Christian Torp-Pedersen (Дания).
ESC Комитет CPG: Silvia G. Priori (Председатель, Италия), Maria Angeles Alonso Garsía (Испания), JeanJacues Blanc (Франция), Andrzej Budaj (Польша), Martin Cowie (Великобритания), Veronica Dean (Франция), Jaap Deckers (Нидерланды), Enrique Fernandez Burgos (Испания), John Lekakis (Греция), Bertil Lindahl (Швеция), Gianfranco Mazzotta (Италия), Keith McGregor (Франция), Joâao Marais (Португалия), Ali Oto (Турция), Otto A. Smiseth (Норвегия).
Рецензенты: Maria Angeles Alonso Garsía (Рецензионный координатор CPG, Испания); Diego Ardissino (Италия), Cristina Avendano (Испания), Carina Blomström-Lundqvist (Швеция), Denis Clement (Бельгия), Helmut Drexler (Германия), Roberto Ferrari (Италия), Keith A.Fox (Великобритания), Desmond Julian (Великобритания), Peter Kearney (Ирландия), Wener Klein (Австрия), Lars Köber (Дания), Giuseppe Mancia (Италия), Markku Nieminen (Финляндия), Witold Ruzyllo (Польша), Maarten Simoons (Нидерланды), Kristian Thygesen (Дания), Gianni Tognoni (Италия), Isabella Tritto (Италия), Lars Wallentin (Швеция).
Оригинальный текст документа, подготовленный Рабочей группой Европейского общества кардиологов, опубликован в European Heart Journal 2004; 25(15): 1341-62.
Список литературы
1. Cruickshank JM, Prichard BNC. Beta-adrenoceptors. In: Cruickshank JM, Prichard BNC, editors. Beta-blockers in clinical practice. London: Churchill Livingstone 1996; 9-86.
2. Tamargo JL, Delpon E. Optimisation of b-blockers pharmacology. J Cardiovasc Pharmacol 1990;16(Suppl. 5):S8-10.
3. Frishman WH, Lazar EJ, Gorodokin G. Pharmacokinetic optimization of therapy with beta-adrenergic-blocking agents. Clin Pharmacokinet 1991; 20:311-8.
4. Frishman WH. Carvedilol. N Engl J Med 1998; 339:1759-65.
5. Benfield P, Sorkin EM. Esmolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 1987; 33:392-412.
6. Bristow MR. Pathophysiologic and pharmacologic rationale for clinical management of chronic hart failure with beta-blocking agents. Am J Cardiol 1993; 71:12C-22.
7. Bouzamondo A, Hulot JS, Sanchez P, et al. Beta-blocker treatment in heart failure. Fundam Clin Pharmacol 2001; 15:95-109.
8. Waagstein F. Beta-blockers in congestive heart failure: the evolution of a new treatment concept-mechanism of action and clinical implications. J Clin Basic Cardiol 2002; 5:215-23.
9. Man in’t Veld AJ, van der Meiracker A, Schalekamp MA. The effect of beta-adrenoceptor antagonists on total peripheral resistance. J Cardiovasc Pharmacol 1986; 8(Suppl. 4):S49-60.
10. Frishman WH. Multifactorial actions of beta-adrenergic-blocking drugs in ischemic heart disease: current concepts. Circulation 1983; 67(Suppl. I):I11-8.
11. Opie LH. Effect of beta-adrenergic blockade on biochemical and metabolic response to exercise. Am J Cardiol 1985; 55:95D.
12. Kukin ML, Kalman J, Charney R et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999; 102:2646-51.
13. Cleland JG, Dargie HJ. Arrhythmias, catecholamines and electrolytes. Am J Coll Cardiol 1988; 62:55-9.
14. Shizukuda Y, Buttrick PM, Geenen D, et al. Beta-adrenergic stimulation causes cardiocyte apoptosis: influence of tachycardia and hypertrophy. Am J Physiol 1998; 275:961-8.
15. Lowes BD, Gilbert EM, Abraham WT, et al. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 2002; 346:1357-65.
16. Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomized trial. Lancet 1981; ii:823-87.
17. Hjalmarson_A, Goldstein S, Fagerberg B, et al. for the MERITHF Study Group: Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. The metoprolol CR/Xl randomized intervention trial in congestive heart failure (MERIT-HF). JAMA 2000; 283:- 1293-302.
18. Thadani U, Whitsett TL. Beta-adrenergic-blockers and intermittent claudication: time for reappraisal. Arch Int Med 1991; 151:1705-7.
19. Radack K, Deck C. β-Adrenergic blocker therapy does not worsen intermitent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Int Med 1991; 151:1769-76.
20. Kjekshus J, Gilpin E, Gali G, et al. Diabetic patients and beta blockers after acute myocardial infarction. Eur Heart J 1990; 11: 43-50.
21. Gottlieb S, McCarter R, Vogel R. Effect of beta-blockade on mortality among high risk patients after myocardial infarction. N Engl J Med 1998; 338: 489-97.
22. Poole-Wilson P. COMET study. European Congress of Cardiology. Vienna, September 2003.
23. Chen J, Radford MJ, Wang Y, et al. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol 2001; 37:1950-6.
24. Salem S, McDevitt D. Central effects of beta-adrenoceptor antagonists. Clin Pharmacol Ther 1983; 33:52-7.
25. Houston MC, Hodge R. Beta-adrenergic blocker withdrawal syndromes in hypertension and other cardiovascular diseases. Am Heart J 1988; 116:515-23.
26. Psaty BM, Koepsell TD, Wagner EH, et al. The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. JAMA 1990; 263:1653-7.
27. Salpeter SR, Ormiston TM, Salpeter EE, et al. Cardioselective betablockers for chronic obstructive pulmonary disease: a metaanalysis. Respir Med 2003; 97:1094-101.
28. Andrus MR, Holloway KP, Clark DB. Use of beta-blockers in patients with COPD. Ann Pharmacother 2004; 38:142-5.
29. Heintzen MP, Strauer BE. Peripheral vascular effects of betablockers. Eur Heart J 1994; 15:2-7.
30. Gheorghiade M, Goldstein S. Blockers in the post-myocardial infarction patient. Circulation 2002; 106:394-8.
31. Haas SJ, Vos T, Gilbert RE, et al. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of largescale clinical trials. Am Heart J 2003; 146:848-53.
32. Blaufarb I, Pfeifer TM, Frishman WH. Beta-blockers: drug interactions of clinical significance. Drug Safety 1995; 13:359-70.
33. Van de Werf et al, for the task force of the management of acute myocardial infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2003; 24:28-66.
34. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction) ACC/AHA. Guidelines for the management of patients with acute myocardial infarction American College of Cardiology. Available from: www. acc.org September 1999.
35. Priori SG, Aliot E, Blomström-Lundqvist C, et al. for the Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 2001; 22:1374-450.
36. Waagstein F, Hjalmarson_ÅC, Wasir HS. Apex cardiogram and systolic time intervals in acute myocardial infarction and effect of practolol. Br Heart J 1974;1109-21.
37. Hjalmarson Å, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomized trial. Lancet 1981;ii:823-7.
38. Richterova A, Herlitz J, Holmberg S, et al. The Goeteborg Metoprolol Trial in Acute Myocardial Infarction. Effects on chest pain. Am J Cardiol 1984; 53:32D-6.
39. Norris RM, Brown MA, Clarke ED, et al. Prevention of ventricular fibrillation during acute myocardial infarction by intravenous propranolol. Lancet 1984; 2:883-6.
40. ISIS-1 (First International Study of Infarct Survival) collaborative group. Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986; II:57-66.
41. The MIAMI Trial Research Group: Metoprolol in acute myocardial infarction (MIAMI). Am J Cardiol 1985; 56:1G-57.
42. Ryden L, Ariniego R, Arnman K, et al. A double-blind trial of metoprolol in acute myocardial infarction. Effects on ventricular tachyarrhythmias. N Engl J Med 1983; 308:614-8.
43. Yusuf S, Lessem J, Pet J, et al. Primary and secondary prevention of myocardial infarction and strokes. An update of randomly allocated controlled trials. J Hypertens 1993; 11:(Suppl. 4):S61-73.
44. Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction. Systematic review and meta regression analysis. BMJ 1999; 1730-7.
45. Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred betablockade following thrombolytic therapy in patients with acute myocardial infarction (TIMI) IIB study. Circulation 1991; 83:422-37.
46. Van de Werf F, Janssens L, Brzostek T, et al. Short term effect of early intravenous treatment with beta-adrenergic blocking agents or a specific bradycardia agent in patients with acute myocardial infarction receiving thrombolytic therapy. J Am Coll Cardiol 1993; 22:407-16.
47. Barron HV, Rundle AC, Gore JM, et al. for the Participants in the national registry of myocardial infarction-2. Intracranial hemorrhage rates and effect of immediate beta-blocker use in patients with acute myocardial infarction treated with tissue plasminogen activator. Am J Cardiol 2000; 85:294-8.
48. Pfisterer M, Cox JL, Granger CG, et al. Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction. The GUSTO-I experience. Global utilization of streptokinase and TPA (alteplase) for occluded coronary arteries. J Am Coll Cardiol 1998; 32:634-40.
49. Harjai KJ, Stone GW, Boura J, et al. Effects of prior beta-blocker therapy on clinical outcomes after primary coronary angioplasty for acute myocardial infarction. Am J Cardiol 2003; 91:655-60.
50. Halkin A, Nikolsky E, Aymong E, et al. The survival benefit of periprocedural beta-blockers in patients with acute myocardial infarction undergoing primary angioplasty is determined by use of these drugs before admission. Am J Cardiol 2003; 92(Suppl. L):228L.
51. Kernis SJ, Arguya KJ, Boura J, et al. Does beta-bloquer therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? A pooled analisis from the primary angioplasti in myocardial infarction-2 (PAMI-2), No surgery on-site (noSOS), stetn PAMI and Air PAMI trials. Circulation 2003; 108(Suppl. IV):416-7.
52. Wood D, De Backer G, Faergeman O, et al. for the Second Joint Task Force of European and other Societiesy on Coronary Prevention: European Society of Cardiology, European Atherosclerosis Society, European Society of Hypertension, International Society of Behavioural Medicine, European Society of General Practice/Family Medicine, European Network. Prevention of coronary heart disease in clinical practice. Eur Heart J 1998; 19:1434-503.
53. Gibbons RJ, Chatterjeee K, Daley J, et al. for the task force on practice guidelines, ACC/AHA/ACP-ASIM. Guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol 1999; 33:2092-197.
54. Eagle KA, Berger PB, Calkins H, et al. for the task force. ACC/ AHA guideline update on perioperative cardiovascular evaluation for noncardiac surgery. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2002; 105:1257-67.
55. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure) ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult 2002. Available from: http://www.acc.org.
56. Grundy SM, Ivor J, Benjamin IJ, et al. Diabetes and cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation 1999; 100:1134-46.
57. Smith SC, Blair SN, Bonow RO, et al. AHA/ACC Guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 2001; 104:1577-9.
58. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. for the Third Joint Task Force of the European and other Societies on cardiovascular disease prevention in clinical practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24:1601-10.
59. Soumerai SB, McLaughlin TJ, Spiegelman D, et al. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 1997; 277:115-21.
60. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin: The Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS) Eur Heart J 2002; 23:1190-201.
61. The beta-blocker heart attack study group. The beta-blocker heart attack trial. JAMA 1981; 246:2073-4.
62. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304:801-7.
63. Pedersen TR. Six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction. Engl J Med 1985; 313:1055-8.
64. Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomized trial. Lancet 1981; 2:823-7.
65. Boissel JP, Leizorovicz A, Picolet H, et al. Secondary prevention after high-risk acute myocardial infarction with low dose acebutolol. Am J Cardiol 1990; 66:251-60.
66. The CAPRICORN investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction. The CAPRICORN randomised trial. Lancet 2001; 357:1385-90.
67. The beta-blocker pooling project research group. The beta-blocker pooling project. Subgroup findings from randomized trials in postinfarction patients. Eur Heart J 1988; 9:8-16.
68. Hedblad J, Wikstrand L, Janzon H, et al. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the beta-blocker cholesterol-lowering asymptomatic plaque study (BCAPS). Circulation 2001; 103:1721-6.
69. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI study group.. Br Med J 1997; 314:1512-5.
70. Bertrand ME, Simoons ML, Fox KAA, et al. for the task force of
71. the European Society of Cardiology. Management of acute coronary syndromes: acute coronary syndromes without persistent ST-segment elevation. Eur Heart J 2000; 21:1406-32.
72. Bertrand ME, Simoons ML, Fox KAA, et al. for the task force on the management of acute coronary syndromes of the European Society of Cardiology. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002; 23:1809-40.
73. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina) ACC/AHA guideline update for the management of patients with unstable angina and non ST-segment elevation myocardial infarction. American Heart Association; 2002. Available from: www.americanheart.org.
74. Gottlieb S, Weisfeldt ML, Ouyang P, et al. Effect of the addition of propranolol to therapy with nifedipine for unstable angina pectoris: a randomized, double-blind, placebo-controlled trial. Circulation 1986; 3:331-7.
75. Telford A, Wilson C. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet 1981; 1:1225-8.
76. Lubsen JTJ. Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Interuniversity Nifedipine/metoprolol Trial (HINT). Am J Cardiol 1987; 60:18A-25.
77. Yusuf S, Witte J, Friedman L. Overview of results of randomized trials in heart disease: unstable angina, heart failure, primary prevention with aspirin and risk factor modifications. JAMA 1988; 260:2259-63.
78. Ellis K, Tcheng JE, Sapp S, et al. Mortality benefit of beta blockade in patients with acute coronary syndromes undergoing coronary intervention: pooled results from the Epic, Epilog, Epistent, Capture and Rapport Trials. J Interv Cardiol 2003; 16:299-305.
79. Tilmant PY, Lablanche JM, Thieuleux FA, et al. Detrimental effect of propranolol in patients with coronary arterial spasm countered by combination with diltiazem. Am J Cardiol 1983; 52:230-3.
80. Task Force of the European Society of Cardiology. Management of stable angina pectoris. Eur Heart J 1997; 18:394-413. 80. Wang TJ, Stafford RS. National patterns and predictors of betablocker use in patients with coronary artery disease. Arch Int Med 1998; 158:1901-6.
81. Ryden L. Efficacy of epanolol versus metoprolol in angina pectoris: report from a Swedish multicentre study of exercise tolerance. J Int Med 1992; 231:7-11.
82. Boberg J, Larsen FF, Pehrsson SK. The effects of beta blockade with (epanolol) and without (atenolol) intrinsic sympathomimetic activity in stable angina pectoris. The Visacor Study Group. Clin Cardiol 1992; 15:591-5.
83. Frishman WH, Heiman M, Soberman J, et al. Comparison of celiprolol and propranolol in stable angina pectoris. Celiprolol International Angina Study Group. Am J Cardiol 1991; 67:665-70.
84. Cruickshank JM, Prichard BNC. Arrhythmias. In: Cruickshank JM, Prichard BNC, editors. Beta-blockers in clinical practice. London: Churchill Livingstone; 1996; 631-704.
85. Gruppo italiano per lo studio della sopravvivenza nell-infarto miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343:1115-22.
86. Prida XE, Hill JA, Feldman RL. Systemic and coronary hemodynamic effects of combined alpha- and beta-adrenergic blockade (labetalol) in normotensive patients with stable angina pectoris and positive exercise stress test responses. Am J Cardiol 1987; 59:1084-8.
87. Capone P, Mayol R. Celiprolol in the treatment of exercise induced angina pectoris. J Cardiovasc Pharmacol 1986; 8(Suppl. 4): S135-7.
88. Mulcahy D, Cunningham D, Crean P, et al. Circadian variations of total ischemic burden and its alterations with anti-anginal agents. Lancet 1988; i:755-88.
89. Hauf-Zachariou U, Blackwood RA, Gunawardena KA, et al. Carvedilol versus verapamil in chronic stable angina: a multicentre trial. Eur J Clin Pharmacol 1997; 52:95-100.
90. McLenachan JM, Findlay IN, Wilson JT, et al. Twenty-four hour betablockade in stable angina pectoris: a study of atenolol and betaxolol. J Cardiovasc Pharmacol 1992; 20:311-5.
91. Pepine CJ, Cohn PF, Deedwania PC, et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST). Circulation 1994; 90:762-8.
92. Wallace WA, Wellington KL, Chess MA, et al. Comparison of nifedipine gastrointestinal therapeutic system and atenolol on antianginal efficacies and exercise hemodynamic responses in stable angina pectoris. Am J Cardiol 1994; 73:23-8.
93. de Vries RJ, van den Heuvel AF, Lok DJ, et al. Nifedipine gastrointestinal therapeutic system versus atenolol in stable angina pectoris. The Netherlands Working Group on Cardiovascular Research (WCN). Int J Cardiol 1996; 57:143-50.
94. Fox KM, Mulcahy D, Findlay I, et al. The total ischaemic burden european trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. The TIBET Group. Eur Heart J 1996; 17:96-103.
95. van de Ven LL, Vermeulen A, Tans JG, et al. Which drug to choose for stable angina pectoris: a comparative study between bisoprolol and nitrates. Int J Cardiol 1995; 47:217-23.
96. Waysbort J, Meshulam N, Brunner D. Isosorbide-5-mononitrate and atenolol in the treatment of stable exertional angina. Cardiology 1991; 79(Suppl. 2):19-26.
97. Kawanishi DT, Reid CL, Morrison EC, et al. Response of angina and ischemia to long-term treatment in patients with chronic stable angina: a double-blind randomized individualized dosing trial of nifedipine, propranolol and their combination. J Am Coll Cardiol 1992; 19:409-17.
98. Meyer TE, Adanms C, Commerford P. Comparison of the efficacy of atenolol and its combination with slow-release nifedipine in chronic stable angina. Cardiovasc Drugs Ther 1993; 7:909-13.
99. Steffensen R, Grande P, Pedersen F, et al. Effects of atenolol and diltiazem on exercise tolerance and ambulatory ischaemia. Int J Cardiol 1993; 40:143-53.
100. Parameshwar J, Keegan J, Mulcahy D, et al. Atenolol or nicardipine alone is as efficacious in stable angina as their combination: a double blind randomised trial. Int J Cardiol 1993; 40:135-41.
101. Foale RA. Atenolol versus the fixed combination of atenolol and nifedipine in stable angina pectoris. Eur Heart J 1993;14: 1369-74.
102. Rouleau JL, Talajic M, Sussex B, et al. Myocardial infarction patients in the 1990s – their risk factors, stratification and survival in Canada: the Canadian assessment of myocardial infarction (CAMI) Study. J Am Coll Cardiol 1996; 27:1119-27.
103. Egstrup K. Transient myocardial ischemia after abrupt withdrawal of antianginal therapy in chronic stable angina. Am J Cardiol 1988; 61:1219-22.
104. Dargie HJ, Ford I, Fox KM. Total ischaemic burden european trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group. Eur Heart J 1996; 17:104-12.
105. Rehnqvist N, Hjemdahl P, Billing E, et al. Treatment of stable angina pectoris with calcium antagonists and beta-blockers. The APSIS study. angina prognosis study in Stockholm. Cardiologia 1995; 40(Suppl. 1):301.
106. von Arnim T. Medical treatment to reduce total ischemic burden: total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. The TIBBS Investigators. J Am Coll Cardiol 1995; 25:231-8.
107. Savonitto S, Ardissiono D, Egstrup K, et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the international multicenter angina exercise (IMAGE) study. J Am Coll Cardiol 1996; 27:311-6.
108. Remme WJ, Swedberg K: Task Force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22:1527-60.
109. Komajda M, Follath F, Swedberg K, et al. for the study group of diagnosis of the working group on heart failure of the European Society of Cardiology. The Euro heart failure survey programme – a survey on the quality of care among patients with heart failure in Europe: Part 2: treatment, Eur Heart J 2003; 24:464-74.
110. Waagstein F, Hjalmarson AA, Varnauskas E, et al. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975;37: 1022-36.
111. Swedberg K, Hjalmarson A, Waagstein F, et al. Beneficial effects of long-term beta-blockade in congestive cardiomyopathy. Br Heart J 1980; 44:117-33.
112. Anderson J, Lutz JR, Gilbert EM, et al. A randomized trial of low-dose betablockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 1985; 55:471-5.
113. Engelmeier RS, O’Connell JB, Walsh R, et al. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebocontrolled trial. Circulation 1985; 72:536-46.
114. Waagstein F, Bristow MR, Swedberg K, et al. for the MDC Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993; 342:1441-6.
115. CIBIS investigators and committees. A randomized trial of betablockade in heart failure. The cardiac insufficiency bisoprolol study (CIBIS). Circulation 1994; 90:1765-73.
116. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334:1349-55.
117. Colucci WS, Packer M, Bristow MR, et al. for the US carvedilol heart failure study group. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996; 94:2800-6.
118. Bristow MR, Gilbert EM, Abraham WT, et al. for the MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94: 2807-16.
119. Australia/New Zealand heart failure research collaborative group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349: 375-80.
120. Lechat P, Packer M, Chalon S, et al. Clinical effects of betaadrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998; 98:1184-91.
121. CIBIS-II investigators and committees. The cardiac insufficiency bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353:9-13.
122. MERIT-HF study group. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999; 353:2001-7.
123. The RESOLVD Investigators. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy. Circulation 2000; 101:378-84.
124. Packer M, Coats AJS, Fowler MB, et al. for the carvedilol prospective randomized cumulative survival study group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344:1651-8.
125. Doughty RN, Whalley GA, Gamble G, et al. on behalf of the Australia-New Zealand Heart Failure Research Collaborative Group. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol 1997; 29:1060-6.
126. Shekelle PG, Rich MW, Morton SC, PHD, et al. Efficacy of angiotensinconverting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status. A meta-analysis of major clinical trials. J Am Coll Cardiol 2003; 41:1529-38.
127. Metra M, Giubbini R, Nodari S, et al. Differential effects of betablockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 2000; 102:546-51.
128. Bolger AP, Al-Nasser F. Beta-blockers for chronic heart failure: surviving longer but feeling better. Int J Cardiol 2003; 92:1-8.
129. Goldstein S, Fagerberg B, Hjalmarson A, et al. Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study. J Am Coll Cardiol 2001; 38:932-8.
130. The beta-blocker evaluation of survival trial investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344:1659-67.
131. Torp-Pedersen C, Kшber L, Ball S, et al. The incomplete bucindolol evaluation in acute myocardial infarction trial (BEAT. Eur J Heart Fail 2002; 4:495.
132. Poole-Wilson PA, Swedberg K, Cleland JCF, et al. for the COMET investigators Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol european trial (COMET): randomised controlled trial. Lancet 2003; 362:7-13.
133. MacMurray J, Cohen-Solal A, Dietz R, et al. Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice. Eur J Heart Failure 2001; 3:495-502.
134. Herlitz J, Waagstein F, Lindqvist J, et al. Effect of metoprolol on the prognosis for patients with suspected acute myocardial infarction and indirect signs of congestive heart failure (a subgroup analysis of the Goteborg Metoprolol Trial. Am J Cardiol 1997; 80:40J-4.
135. Nieminen M, Böhm M, Germany; Helmut Drexler H, et al. for the European Society of Cardiology Task Force on Acute Heart Failure. Guidelines for the diagnosis and treatment of acute heart failure. Eur Heart J (will be submitted to the European Heart Journal in 2004).
136. Fuster V, Ryden LE, Asinger RW, et al. for the ACC/ AHA/ESC task force. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines and policy conferences (committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur Heart J 2001; 1852-923.
137. Blomström-Lundqvist C, Scheinman MM, Aliot EM, et al. ACCC/AHA/ESC Guidelines for he management of patients with supraventricular arrhythmias A report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur Heart J 2003; 24:1857-97.
138. Turner P, Granville-Grosman KL, Smart JV. Effect of adrenergic receptor blockade on the tachycardia of toritoxicosis and anxiety state. Lancet 1965; 2:1316-8.
139. Delarue NC, Morrow JD, Kerr JH, Colapinto RF. Phaeocromocytoma in the modern context. Can J Surg 1978; 21:387-94.
140. Singh BN. Clinical aspects of the antiarrhythmic action of betareceptor blocking drugs. Part 1. Pattern of response of common arrhythmias. NZ Med J 1973; 78:482-6.
141. Rehnqvist N. Clinical experience with intravenous metoprolol in supraventricular tachyarrhythmias. A multicentre study. Ann Clin Res 1981; 13(Suppl. 30):68-72.
142. Sweany AE, Moncloa F, Vickers FF, et al. Antiarrhythmic effects of intravenous timolol in supraventricular arrhythmias. Clin Pharmacol Ther 1985; 37:124-7.
143. McBride JW, McCoy HG, Goldenberg IF. Supraventricular tachycardia treated with continuous infusion of propranolol. Clin Pharmacol Ther 1988; 44:93-9.
144. Jordaens L, Gorgels A, Stroobandt R, et al. Efficacy and safety of intravenous sotalol for the termination of paroximal supraventricular tachycardia. Am J Cardiol 1991; 68:35-40.
145. Cruickshank JM, Prichard BNC. Arrhythmias. In: Cruickshank JM, Prichard BNC, editors. Beta-blockers in clinical practice. London: Churchill Livingstone; 1996:705-63.
146. Gibson DG, Sowton E. The use of beta-adrenergic receptor blocking drugs in dysrrhythmias. Prog Cardiovasc Dis 1969; 12:16-39.
147. Klein GJ, Bashore TM, Sellers T, et al. Ventricular fibrillation in the Wolff–Parkinson–White syndrome. N Engl J Med 1979; 301:1080-5.
148. Dreifus LS, Haiat R, Watanabe Y, et al. Ventricular fibrillation: a possible mechanism of sudden cardiac death in patients and Wolff– Parkinson–White syndrome. Circulation 1971; 43:520-7.
149. Prystowsky EN, Benson Jr DW, Fuster V, et al. Management of patients with atrial fibrillation: a statement for healthcare professionals from the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation 1996; 93:1262-77.
150. Steeds RP, Birchall AS, Smith M, et al. An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation. Heart 1999; 82:170-5.
151. Kuhlkamp V, Schirdewan A, Stangl K, et al. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2000; 36:139-46.
152. National High Blood Pressure Education Program. Report of the national high blood pressure education program working group on high blood pressure in pregnancy. Am J Obstet Gynecol 2000; 183:S1-22.
153. Platia EV, Michelson EL, Porterfield JK, et al. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol 1989; 63:925-9.
154. Lewis RV, McMurray J, McDevitt DG. Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalized patients with chronic atrial fibrillation. J Cardiovasc Pharmacol 1989; 13:1-6.
155. Farshi R, Kistner D, Sarma JS, et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open label of five drug regimens. J Am Coll Cardiol 1999; 33:304-10.
156. Gulamhusein S, Ko P, Klein GJ. Ventricular fibrillation following verapamil in the Wolff-Parkinson-White syndrome. Am Heart J 1983; 106:145-7.
157. Khand AU, Rankin AC, Martin W, et al. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure. J Am Coll Cardiol 2003; 42:1- 944-51.
158. Balser JR, Martinez EA, Winters BD, et al. Beta-adrenergic blockade accelerates conversion of postoperative supraventricular tachyarrhythmias. Anesthesiology 1998; 89:1052-9.
159. Plewan A, Lehmann G, Ndrepepa G, et al. Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol. Eur Heart J 2001; 22:1504-10.
160. Katritsis D, Panagiotakos DB, Karvouni E, et al. Comparison of effectiveness of carvedilol versus bisoprolol for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. Am J Cardiol 2003; 92:1116-9.
161. Singh BN, Jewitt DE. Beta-adrenoreceptor blocking drugs in cardiac arrhythmias. Cardiovasc Drugs 1997; 2:119-59.
162. Mosca L, Scott M, Grundy SM, et al. Guide to preventive cardiology for women. AHA/ACC scientific statement. Circulation 1999; 99:2480-4.
163. Priori SG, Aliot E, Blomstroem-Lundqvist C, et al. Update of the guidelines on sudden cardiac death of the European Society of Cardiology. Eur Heart J 2003; 24:13-5.
164. Meltzer LE, Kitchell JR. The development and current status of coronary care. En: Textbook of coronary care. Excerpta Medica (Amsterdam) 1972; 3-25.
165. Milner PG, Platia EV, Reid PR, et al. Ambulatory electrocardiographic recordings at the time of fatal cardiac arrest. Am J Cardiol 1985; 56:588-92.
166. Marcus FI, Cobb LA, Edwards JE, et al. Mechanism of death and prevalence of myocardial ischemic symptoms in the terminal event after acute myocardial infarction. Am J Cardiol 1988; 61:8-15.
167. Farb A, Tang AL, Burke AP, et al. Sudden coronary death. Frequency of active coronary lesions, inactive coronary lesions, and myocardial infarction. Circulation 1995; 92:1701-9.
168. Ryden L, Ariniego R, Arnman K, et al. A double blind trial of metoprolol in acute myocardial infarction. N Engl J Med 1983; 308:614-8.
169. Rossi PR, Yusuf S, Ramsdale D, et al. Reduction of ventricular arrhythmias by early intravenous atenolol in suspected acute myocardial infarction. Br Med J 1983; 286:506-10.
170. Nuttal SL, Toescu V, Kendall MJ. Beta-blockade after myocardial infarction. BMJ 2000; 320:581-8.
171. Held P. Effects of beta blockers on ventricular dysfunction after myocardial infarction:tolerability and survival effects. Am J Cardiol 1993; 71:39C-44.
172. Kendall MJ, Lynch KP, Hjalmarson A, et al. Beta-blockers and sudden cardiac death. Ann Int Med 1995; 123:358-67.
173. Maron BJ. Hypertrophic cardiomyopathy. Lancet 1997; 350:127-33.
174. Spirito P, Seidman CE, McKenna WJ, et al. The management of hypertrophic cardiomyopathy. N Engl J Med 1997; 336:775-85.
175. McKenna W, Deanfield J, Faruqui A, et al. Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and haemodynamic features. Am J Cardiol 1981; 47:532-8.
176. Maron BJ, McKenna W, Danielson GK, et al for the American College of Cardiology/European Society of Cardiology clinical expert task force. Hypertrophic cardiomyopathy. Eur Heart J 2003; 24:1965-91.
177. Desseigne P, Tabib A, Loire R. Myocardial bridging on the left anterior descending coronary artery and sudden cardiac death. Apropos of 19 cases with autopsy. Arch Mal Coeur Vaiss 1991; 84:511-6.
178. Schwarz ER, Klues HG, Vom DJ, et al. Functional, angiographic and intracoronary Doppler flow characteristics in symptomatic patients with myocardial bridging: effect of short-term intravenous betablocker medication. J Am Coll Cardiol 1996; 27:1637-45.
179. Schwartz PJ, Priori SG, Napolitano C. The long QT syndrome. In: Zipes DP, Jalife J, editors. Cardiac electrophysiology From cell to bedside. Philadelphia: WB Saunders; 2000;597-615.
180. Moss AJ, Schwartz PJ, Crampton RS, et al. The long QT syndrome. Prospective longitudinal study of 328 families. Circulation 1991; 84:1136-44.
181. Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype phenotype correlation in the long-QT syndrome: gene specific triggers for lifethreatening arrhythmias. Circulation (Online) 2001; 103:89-95.
182. Coumel P, Fidelle J, Lucet V, et al. Catecholaminergic-induced severe ventricular arrhythmias with Adams-Stokes syndrome in children: report of four cases. Br Heart J 1978; 40:28-37.
183. Leenhardt A, Lucet V, Denjoy I, et al. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation 1995; 91:1512-9.
184. Myerburg RJ, Kessler KM, Zaman L, et al. Survivors of prehospital cardiac arrest. JAMA 1982; 247:1485-90.
185. Priori SG, Crotti L. Idiopathic ventricular fibrillation. Cardiac Electrophysiol Rev 1999; 3:198-201.
186. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 1992; 20:1391-6.
187. Thakkar RB, Oparil S. What do international guidelines say about therapy. Hypertension 2001; 19(Suppl. 3):S23-31.
188. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. JAMA 2003; 289:2560-72.
189. Guidelines subcommittee. 1999 World Health Organization-international Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17:151-8.
190. Dahlöf B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-Hypertension). Lancet 1991; 338:1281-5.
191. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: Principal results. Br Med J 1985; 291:97-104.
192. Olsson G, Tuomilehto J, Berglund G, et al. Primary prevention of sudden cardiovascular death in hypertensive patients. Mortality results from the MAPHY study. Am J Hypertens 1991; 4:151-8.
193. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA 1997; 277:739-45.
194. Maphy and the two arms of Happhy. JAMA 1989; 262:3272-4.
195. Goldstein LB, Adams R, Becker K, et al. Primary prevention of ischemic stroke. A statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation 2001; 103:163-82.
196. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood pressure lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 355:1955-64.
197. Hansson L, Lindholm LH, Niskanen L, et al. for the Captopril Prevention Project (CAPPP) study group. Effect of angiotensinconverting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353:611-6.
198. Hansson L, Lindholm LH, Ekbom T, et al. for the STOP-Hypertension-2 study group. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial. Lancet 1999; 354:1751-6.
199. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type-2 diabetes-UKPDS-38. BMJ 1998;317:703–13.
200. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction. A meta-analysis. Lancet 2001; 358:1- 305-15.
201. Dahl€of B, Devereux RB, Kjeldsen SE, et al. for the LIFE study group. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE):a randomized trial against atenolol. Lancet 2002; 359:995-1003.
202. Erbel R, Alfonso F, Boileau C, et al. for the task force of the European Society of Cardiology: Diagnosis and management of aortic dissection. Recommendations of the task force on aortic dissection, European Society of Cardiology. Eur Heart J 2001; 22:1642-81.
203. DeSanctis RW, Doroghazi RM, Austen WG, et al. Aortic dissection. N Engl J Med 1987; 317:1060-7.
204. Isselbacher EM. Diseases of the aorta. In: Braunwald E, Zipes DP, Libby P, editors. Heart disease. Philadelphia: WB Saunders; 2001; 1422-56.
205. Siddiqui AK, Ahmed S, Delbeau H, et al. Lack of physician concordance with guidelines on the perioperative use of beta-blockers. Arch Int Med 2004; 164:664-7.
206. Magnusson J, Thulin T, Werner O, et al. Haemodynamic effects of pretreatment with metoprolol in hypertensive patients undergoing surgery. Br J Anaesth 1986; 58:251-60.
207. Stone JG, Foex P, Sear JW, et al. Risk of myocardial ischaemia during anaesthesia in treated and untreated hypertensive patients. Br J Anaesth 1988; 61:675-9.
208. Stone JG, Foex P, Sear JW, et al. Myocardial ischaemia in untreated hypertensive patients: effect of a single small oral dose of a betaadrenergic blocking agent. Anesthesiology 1988; 68:495-500.
209. Pasternack PF, Grossi EA, Baumann FG, et al. Beta-blockade to decrease silent myocardial ischaemia during peripheral vascular surgery. Am J Surg 1989; 158:113-6.
210. Pasternack PF, Imparato AM, Baumann FG, et al. The hemodynamics of beta-blockade in patients undergoing abdominal aortic aneurysm repair. Circulation 1987;,76(Suppl. 3):III1-7.
211. Yeager RA, Moneta GL, Edwards JM, et al. Reducing perioperative myocardial infarction following vascular surgery: the potential role of beta-blockade. Arch Surg 1995; 130:869-72.
212. Raby KE, Brull SJ, Timimi F, et al. The effect of heart rate control on myocardial ischemia among high-risk patients after vascular surgery. Anesth Analg 1999; 88:477-82.
213. Jakobsen CJ, Bille S, Ahlburg P, et al. Perioperative metoprolol reduces the frequency of atrial fibrillation after thoracotomy for lung resection. J Cardiothorac Vasc Anesth 1997; 11:746-51.
214. Bayliff CD, Massel DR, Inculet RI, et al. Propranolol for the prevention of postoperative arrhythmias in general thoracic surgery. Ann Thorac Surg 1999; 67:182-6.
215. Mangano DT, Layug EL, Wallace A, et al. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. Engl J Med 1996; 335:1713-20.
216. Poldermans D, Boersma E, Bax JJ, et al. for the Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. N Engl J Med 1999; 341:1789-94.
217. Boersma E, Poldermans D, Bax JJ, et al. Predictors of cardiac events after major vascular surgery: role of clinical characteristics, dobutamine echocardiography, and beta-blocker therapy. JAMA 2001; 285:1865-73.
218. Wallace A, Layug B, Tateo I, et al. for the McSPI Research Group. Prophylactic atenolol reduces postoperative myocardial ischaemia. Anesthesiology. 1998;88:7–17.
219. Brignole M, Menozzi C, Gianfranchi L, et al. A controlled trial of acute and long-term medical therapy in tilt-induced neurally mediated syncope. Am J Cardiol 1992; 70:339-42.
220. Sheldon R, Rose S, Flanagan P, et al. Effects of beta blockers on the time to first syncope recurrence in patients after a positive isoproterenol tilt table test. Am J Cardiol 1996; 78:536-9.
221. Di Gerolamo E, Di Iorio C, Sabatini P, et al. Effects of different treatments vs no treatment on neurocardiogenic syncope. Cardiologia 1998; 43:833-7.
222. Flevari P, Livanis E, Theodorakis G, et al. Neurocardiogenic syncope: prospective, randomized, cross-over evaluation of the effects of propranolol, nadolol and placebo on syncope recurrence and patients’ well-being (Abstr.). PACE 2000; 23:666.
223. Madrid A, Ortega I, Rebollo GJ, et al. Lack of efficacy of atenolol for the prevention of neurally-mediated syncope in highly symptomatic population: a prospective double-blind, randomized and placebo-controlled study. J Am Coll Cardiol 2001; 37:554-7.
224. Fitzpatrick AP, Ahmed R, Williams S, et al. A randomized trial of medical therapy in malignant vasovagal syndrome or neurally mediated bradycardia/hypotension syndrome. Eur J Cardiac Pacing Electrophysiol 1991; 1:191-202.
225. Mahanonda N, Bhuripanyo K, Kangkagate C, et al. Randomized double-blind, placebo-controlled trial of oral atenolol in patients with unexplained syncope and positive upright tilt table test results. Am Heart J 1995; 130:1250-3.
226. Brignole M, Alboni P, Benditt D, et al. for the Task Force on Syncope, European Society of Cardiology. Guidelines on management (diagnosis and treatment) of syncope. Eur Heart J 2001; 22:1256-306.
227. Oakley C, Child A, Iung B, et al. for the Task Force on the management of Cardiovascular diseases during pregnancy of the European Society of Cardiology. Expert consensus document on management of cardiovascular diseases during pregnancy. Eur Heart J 2003; 24: 761-81.
228. Bloomfield TH, Howkins DF. The effect of drugs on human fetus. In: Stechll, Ginsberg, editors. Scientific foundations of obstetric and gynecology. Oxford: Butterworth/Heinemann; 1991; 320-36.
229. Kubo T, Eduardo R, Azevedo, et al. Lack of evidence for peripheral alpha-1 adrenoceptor blockade during long-term treatment of heart failure with carvedilol. J Am Coll Cardiol 2001; 38:1463-9.
Рецензия
Для цитирования:
Документ о соглашении экспертов по блокаторам β-адренергических рецепторов. Кардиоваскулярная терапия и профилактика. 2005;4(1):99-124.
For citation:
Expert consensus document on β-adrenergic receptor blockers. Cardiovascular Therapy and Prevention. 2005;4(1):99-124. (In Russ.)
Просмотров:
347
Послать статью по эл. почте 
